Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shenogen Pharma Group (Shenogen) and Chemizon, a division of Optomagic, have entered into a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Subscribe to our email newsletter
Chemizon will be responsible for a spectrum of activities for an integrated drug development program including lead optimisation, assay development, ADME, DMPK, computational chemistry and animal pharmacology.
Jin Li, president of Shenogen Pharma Group, said: “We are very pleased to enter into this collaboration with Chemizon whose experienced management team has a track record of success in creating promising drug candidates. This collaboration underscores our commitment towards creating orally administered, small molecule modulators of the non-classical Estrogen Receptor pathway that target indications including metastatic breast cancer and osteoporosis.”
Anthony Piscopio, CEO of Chemizon, said: “We are delighted that Shenogen, chose Chemizon as their partner. We expect the synergy resulting from this partnership will result in novel breakthrough therapies that will ultimately benefit patients afflicted with life threatening diseases.”
Shenogen is a privately held drug development venture that develops novel therapeutics and companion diagnostic kits that are targeted at a novel membrane associated estrogen receptor, the ER-alpha 36. Shenogen effectively adopts a virtual pharma strategy by collaborating closely with many US and China-based research and development partners.